吉西他滨联合顺铂治疗老年晚期非小细胞肺癌研究

目的比较吉西他滨联合顺铂方案对老年非小细胞肺癌和非老年非小细胞肺癌的疗效和毒副作用的区别。方法 采用吉西他滨联合顺铂3周方案治疗晚期老年非小细胞肺癌35例, 同期非老年35例作为对照, 观察近期疗效和毒副作用。结果 老年组伴随疾病发生率、化疗前评分及完成化疗周期数较非老年组为高;有效率45.7%∶51.4%, 中位生存时间9.0月∶9.2月, 一年生存率38.2%∶40.6%均无显著性差异;毒副作用也无显著性差异。结论 吉西他滨联合顺铂3周方案对于老年非小细胞肺癌是一个比较安全的选择。

Treatment of advanced non-small-cell lung cancer with gemcitabine plus cisplatin in the elderly patients compared with in the younger

Objective To compare the efficacy and toxicity of gemcitabine plus eisplatin between the elderly patients with advanced non - small - cell lung cancer and the younger. Methods 35 elderly advanced non - small - cell lung cancer patients received chemotherapy with gemeitabine and cisplatin every 3weeks and the 35 younger patients as a comparison. The efficacy and toxicity were observed. Results Compared with the younger patients, the elderly have more co - morbidity and lower KPS score and received fewer cycles of chemotherapy. The response rate,median survival time,and 1 -year survival rate were 45.7% ,9.0 months,38.2% in the elderly and 51.4% ,9.2 months,40.6% in the younger respeetivety. There were no statistical significance between two groups. The toxicity between two group have no statistical significance. Conclusions For the elderly patients with non small cell lung cancer,gemcitabine plus eisplatin every 3 weeks were a safe and effective selection.